Man Group PLC Supernus Pharmaceuticals, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Man Group PLC holds 24,324 shares of SUPN stock, worth $861,799. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,324

Holding current value

$861,799

% of portfolio

0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$25.77 - $35.16 $626,829 - $855,231	24,324 New	24,324 $758,000
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $1.35 Million - $1.62 Million	-49,143 Reduced 81.28%	11,319 $312,000
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $625,119 - $809,456	20,900 Added 52.83%	60,462 $1.82 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $42,020 - $50,562	-1,203 Reduced 2.95%	39,562 $1.43 Million
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $1.27 Million - $1.54 Million	40,765 New	40,765 $1.45 Million
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $291,248 - $361,771	-10,900 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$24.15 - $31.45 $4.63 Million - $6.03 Million	-191,628 Reduced 94.62%	10,900 $285,000
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $899,160 - $1.31 Million	-50,800 Reduced 20.05%	202,528 $5.1 Million
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $1.31 Million - $1.62 Million	64,655 Added 34.27%	253,328 $5.28 Million
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $1.07 Million - $1.56 Million	62,582 Added 49.63%	188,673 $4.48 Million
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $131,133 - $224,061	9,075 Added 7.76%	126,091 $2.27 Million
Q4 2019 Feb 18, 2020	BUY	$19.93 - $29.13 $1.2 Million - $1.75 Million	60,225 Added 106.05%	117,016 $2.78 Million
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $417,988 - $547,635	16,411 Added 40.64%	56,791 $1.56 Million
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $2.91 Million - $3.77 Million	-97,077 Reduced 70.62%	40,380 $1.34 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $4.3 Million - $5.51 Million	131,109 Added 2065.36%	137,457 $4.82 Million
Q4 2018 Feb 14, 2019	SELL	$30.84 - $49.51 $3.32 Million - $5.33 Million	-107,662 Reduced 94.43%	6,348 $211,000
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $2.31 Million - $3.06 Million	-54,142 Reduced 32.2%	114,010 $5.74 Million
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $2.87 Million - $3.89 Million	-65,062 Reduced 27.9%	168,152 $10.1 Million
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $8.66 Million - $10.9 Million	233,214 New	233,214 $10.7 Million

Others Institutions Holding SUPN

# of Institutions

281

Shares Held

60.6M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$368 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$217 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$181 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$102 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$93.2 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account